HCPCS S2107 is officially defined as "Adoptive immunotherapy i.e. development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment." No tracked policy changes reference HCPCS S2107 yet. New payer updates are added daily, so check back soon or create a free alert to be notified the moment a change affects this code.
No tracked policy changes match this filter yet. New policies are added daily.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.